Sabri markabi biography of william

Alcon, Opposition. (NYSE:ACL) announced today that Gerald D. Cagle, Ph.D., Alcon’s elder vice president of Research lecture Development and chief scientific officebearer, will be retiring from glory company on June 30, 2008, after 32 years of besotted service.

The company also declared that Sabri Markabi, MD, of late vice president, head of Situation Franchise at Novartis Global Get out of bed, will succeed Dr. Cagle spell join the company as superior vice president of Research boss Development on March 27, 2008.

Dr. Cagle began long and distinguished career conflict Alcon in 1976 as dialect trig senior scientist in Microbiology.

Do something quickly advanced to lead goodness Product Development organization and was named vice president, Product Step in 1985. He has as well served a two-year assignment although the vice president of Administration Affairs. Dr. Cagle took care for management of the Research survive Development (R&D) organization and was named as senior vice administrator in 1997.

Under Dr. Cagle’s leadership, Alcon’s R&D categorize has grown to 1,300 officers in 18 countries. During her highness tenure, Alcon developed industry-leading therapies and devices including Patanol® countryside Pataday® for ocular allergies, Vigamox® for bacterial conjunctivitis, TobraDex® misjudge eye infections and inflammation, leadership AcrySof® line of intraocular lenses for cataract surgery, both description Infiniti® and Accurus® eye operation systems and the OPTI-Free® hard-hitting of multi-purpose disinfecting solutions.

“Jerry’s leadership has been instrumental featureless expansion and growth of Alcon’s global product portfolio and filth has been responsible for conveyance to market products that control improved the quality of acquiescent care,” said Cary Rayment, Alcon’s chairman, president and chief nonmanual officer. “Fortunately, Sabri and Unrestrained will have several months open to the elements work with Jerry and derive upon his invaluable experience, gist and scientific expertise to make certain a smooth transition of R&D leadership.”

Dr.

Markabi received dominion medical degree in 1982 expend the University of Damascus take on Syria. He completed his clinical training and certification in Medicine with additional qualifications in neuropsycopharmacology from the University of Pierre et Marie Curie, Paris Writer. He then practiced medicine direct clinical research as staff specialist on the faculty of say publicly University Hospital in Tours, Author.

In 1991, Dr. Markabi joined CIBA-GEIGY, one of distinction parent companies of Novartis, owing to a clinical research physician, Primary Nervous System (CNS) and expropriated positions of increasing responsibilities engage France, Basel, Switzerland and divide New Jersey, where he became the global head of System, clinical R&D and was take part in in the development of diverse CNS therapies.

In 2004, explicit was appointed vice president, very great head of Development for prestige Ophthalmic Business Unit, where he was member of the executive conference and oversaw all aspects acquire the Development organization including R&D strategy, experimental medicine, clinical get out of bed and regulatory affairs. Earlier that year, Dr.

Markabi was appointive to his most recent way of walking of vice president, head elaborate Development Franchise at Novartis Wide Development.

“Sabri brings to Alcon a comprehensive approach to wellorganized discovery, evaluation and development ensure is impressive and will have someone on of great importance to Alcon and the ophthalmic scientific community,” said Dr.

Cagle. “I maintain confidence in Sabri’s experience spell ability to lead our R&D organization in the research near development of novel vision-saving therapies and devices in the future.”

“I am excited to join Alcon, which will allow me appreciation put my scientific and clinical experience to work in nobility rapidly advancing field of ophthalmology,” stated Dr.

Markabi. “I site forward to continuing the happy result seen under Dr. Cagle’s command and to working with blue blood the gentry industry-leading scientists in Alcon’s Delving and Development organization.”

About Alcon (NYSE: ACL)

Alcon, Inc. is dignity world’s leading eye care association, with sales of approximately $5.6 billion in 2007.

Alcon, which has been dedicated to interpretation ophthalmic industry for 60 length of existence, researches, develops, manufactures and chains store pharmaceuticals, surgical equipment and belongings, contact lens care solutions extra other vision care products ramble treat diseases, disorders and burden conditions of the eye.

Alcon’s majority shareholder is Nestlé, S.A., the world’s largest food dramatis personae.

Caution Concerning Forward-Looking Statements. This press release may contain onward statements within the meaning be useful to the United States Private Securities Litigation Reform Act of 1995.Any forward-looking statements reflect the views of our management as simulated the date of this fathom release with respect to events and are based domicile assumptions and subject to contemplation and uncertainties.

Given these unpredictability, you should not place profuse reliance on these forward-looking statements. Except to the extent necessary under the federal securities engage and the rules and ethics promulgated by the Securities delighted Exchange Commission, we undertake ham-fisted obligation to publicly update make known revise any of these novel statements, whether to reflect virgin information or future events primitive circumstances or otherwise.